TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Most patients with colorectal cancer die as a result of the disease spreading to other organs. However, no prevalent mutations have been associated with metastatic colorectal cancers. Instead, particular features of the tumour microenvironment, such as lack of T-cell infiltration, low type 1 T-helper cell (T H 1) activity and reduced immune cytotoxicity or increased TGFβ levels predict adverse outcomes in patients with colorectal cancer. Here we analyse the interplay between genetic alterations and the tumour microenvironment by crossing mice bearing conditional alleles of four main colorectal cancer mutations in intestinal stem cells. Quadruple-mutant mice developed metastatic intestinal tumours that display key hallmarks of human microsatellite-stable colorectal cancers, including low mutational burden, T-cell exclusion and TGFβ-activated stroma. Inhibition of the PD-1-PD-L1 immune checkpoint provoked a limited response in this model system. By contrast, inhibition of TGFβ unleashed a potent and enduring cytotoxic T-cell response against tumour cells that prevented metastasis. In mice with progressive liver metastatic disease, blockade of TGFβ signalling rendered tumours susceptible to anti-PD-1-PD-L1 therapy. Our data show that increased TGFβ in the tumour microenvironment represents a primary mechanism of immune evasion that promotes T-cell exclusion and blocks acquisition of the T H 1-effector phenotype. Immunotherapies directed against TGFβ signalling may therefore have broad applications in treating patients with advanced colorectal cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Blockade of the TGFβ signaling pathway promotes enough T cell infiltration to make tumors sensitive to PD-1 therapy [39].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“Cell analysis of human and mouse CRC specimens showed that CAF is a major contributor to TGF-β production [39].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“It has been demonstrated in a variety of tumor models, including CRC models, that activation of CAF may induce PD-1 and CTLA-4 expression on relevant immune cells, which leads to tumor insensitivity to immunotherapy or recurrence [39,304,305,306].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“A landmark study from 2018 demonstrated that TGF-β contributes to immune exclusion in colorectal liver metastasis and that inhibition of the TGF-β receptor 1 using the drug galunisertib enhanced tumorous infiltration with T cells, inhibited outgrowth of liver metastases and synergised with anti-PD-L1 therapy to eradicate established lesions.161”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [161]
In the citing paper
“leading to the proposition that combined TGFβ targeting and immune checkpoint blockade may represent an attractive therapeutic strategy for CMS4 colorectal cancer (34).”
From Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine (2024) · cites this paper as [34]
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
lmerTest Package: Tests in Linear Mixed Effects Models
Kuznetsova, A., Brockhoff, P. B., & Christensen, R. H. B. (2017) · Journal of Statistical Software · doi:10.18637/jss.v082.i13 · Cited by 24,346
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Data Analysis Using Regression and Multilevel/Hierarchical Models
Gelman, A., & Hill, J. (2006) · doi:10.1017/cbo9780511790942 · Cited by 13,597
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cited by
Items 301–400 of 1,002
Freeman, P., & Mielgo, A. (2020) · Cancers · doi:10.3390/cancers12092687 · Cited by 102
“In both settings, inhibition of CAF-derived TGF-β resulted in increased T cell accumulation within the tumour parenchyma and restored the efficacy of checkpoint inhibition in preclinical models, reducing metastatic burden [43,44].”
BackgroundMartínez-Usatorre, A., Kadioglu, E., Boivin, G., Cianciaruso, C., Guichard, A., Torchia, B., Zangger, N., Nassiri, S., Keklikoglou, I., Schmittnaegel, M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1616 · Cited by 119
Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy
Liu, L., Huang, X., Shi, F., Song, J., Guo, C., Yang, J., Liang, T., & Bai, X. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02273-w · Cited by 112
Haake, M., Haack, B., Schäfer, T., Harter, P. N., Mattavelli, G., Eiring, P., Vashist, N., Wedekink, F., Genßler, S., Fischer, B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39817-3 · Cited by 132
Castiglioni, A., Yang, Y., Williams, K., Gogineni, A., Lane, R. S., Wang, A. W., Shyer, J. A., Zhang, Z., Mittman, S., Gutierrez, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40398-4 · Cited by 116
“Combining checkpoint blockade with inhibitors of the immunosuppressive cytokine TGF β potentiates curative, CD8 T cell-dependent anti-tumor immunity both in immune-excluded 8,12,13 and other preclinical models 12,14 – 20 .”
The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer
Cai, J., Qi, Q., Qian, X., Han, J. G., Zhu, X., Zhang, Q., & Xia, R. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02879-2 · Cited by 106
Wang, S., Song, Y., Cao, K., Zhang, L., Fang, X., Chen, F., Feng, S., & Yan, F. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.07.051 · Cited by 106
Ansems, M., & Span, P. N. (2020) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2020.04.001 · Cited by 116
The immune microenvironment of colorectal cancer
Kennel, K. B., & Greten, F. R. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00872-1 · Cited by 143
“4).”
Zonation of Ribosomal DNA Transcription Defines a Stem Cell Hierarchy in Colorectal Cancer
Morral, C., Stanisavljevic, J., Hernando-Momblona, X., Mereu, E., Álvarez-Varela, A., Cortina, C., Stork, D., Slebe, F., Turon, G., Whissell, G., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.04.012 · Cited by 98
“To generate liver metastasis, dissociated organoids (single cells) were injected intrasplenically (IS) in NSG mice as described in Calon et al. (2012) and Tauriello et al. (2018).”
MethodSelf-citationHypoxia-driven intratumor heterogeneity and immune evasion
Terry, S., Engelsen, A. S. T., Buart, S., El‐Sayed, W., Venkatesh, G. H., & Chouaïb, S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.004 · Cited by 107
SMAD4 promotes TGF-β–independent NK cell homeostasis and maturation and antitumor immunity
Wang, Y., Chu, J., Yi, P., Dong, W., Saultz, J., Wang, Y., Wang, H., Scoville, S., Zhang, J., Wu, L.-C., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121227 · Cited by 96
Kerdidani, D., Chouvardas, P., Rocañín-Arjó, A., Giopanou, I., Ntaliarda, G., Guo, Y. A., Tsikitis, M., Kazamias, G. M., Potaris, Κ., Stathopoulos, G. T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09370-z · Cited by 104
Zheng, Z., Wieder, T., Mauerer, B., Schäfer, L., Kesselring, R., & Braumüller, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411673 · Cited by 133
“Among the various compounds tested, galunisertib, a small molecule that targets the TGF-β receptor 1 (TGFBR1) kinase activity, has been extensively studied [234].”
BackgroundFibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging
Peltier, A., Seban, R., Buvat, I., Bidard, F., & Mechta‐Grigoriou, F. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.008 · Cited by 102
Xiong, D., Wang, Y., Singavi, A. K., Mackinnon, A. C., George, B., & You, M. (2018) · iScience · doi:10.1016/j.isci.2018.10.021 · Cited by 98
“Collectively, these studies indicate that inhibiting TGF-b could significantly improve the efficacy of anti-PD-1/anti-PD-L1 treatment (Mariathasan et al., 2018; Tauriello et al., 2018).”
BackgroundTurning cold tumors into hot tumors to ignite immunotherapy
Liu, Y., Wang, Y., Wang, S., Li, J., He, W. A., Fan, X.-J., & Wan, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02477-6 · Cited by 136
Targeting the Tumor Microenvironment in Colorectal Peritoneal Metastases
Ceelen, W., Ramsay, R. G., Narasimhan, V., Heriot, A. G., & De Wever, O. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2019.12.008 · Cited by 94
Role of TGF-Beta and Smad7 in Gut Inflammation, Fibrosis and Cancer
Stolfi, C., Troncone, E., Marafini, I., & Monteleone, G. (2020) · Biomolecules · doi:10.3390/biom11010017 · Cited by 95
Zhu, Y.-H., Zheng, J.-H., Jia, Q.-Y., Duan, Z., Yao, H., Yang, J., Sun, Y., Jiang, S.-H., Liu, D., & Huo, Y. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00741-1 · Cited by 111
“Tauriello and colleagues found that PD-1/PD-L1 suppression had a poor response in mouse models, while the addition of TGF-β inhibition had an effective response to tumor cytotoxic T cells, meaning blocking TGF-β signaling transduction made the tumor sensitive to PD-1/PD-L1 therapy [149].”
BackgroundCancer-Associated Fibroblasts in Hepatocellular Carcinoma and Cholangiocarcinoma
Fan, Y., Chan, M. S. M., & Lee, T. K. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.01.006 · Cited by 107
Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy
Vitale, I., Sistigu, A., Manic, G., Rudqvist, N.-P., Trajanoski, Z., & Galluzzi, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.003 · Cited by 94
Rodriguez-Ruiz, M. E., Rodríguez, I., Mayorga, L., Labiano, T., Barbés, B., Etxeberría, I., Ponz‐Sarvisé, M., Azpilikueta, A., Bolaños, E., Sanmamed, M. F., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0558 · Cited by 99
TGF-β Mediated Immune Evasion in Cancer—Spotlight on Cancer-Associated Fibroblasts
Ghahremanifard, P., Chanda, A., Bonni, S., & Bose, P. (2020) · Cancers · doi:10.3390/cancers12123650 · Cited by 108
Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cells
Guo, Y., Lu, X., Chen, Y., Rendon, B. E., Mitchell, R. A., Cuatrecasas, M., Cortés, M., Postigo, A. A., Liu, Y., & Dean, D. C. (2021) · Science Advances · doi:10.1126/sciadv.abd7455 · Cited by 100
TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
Yi, M., Li, T., Niu, M., Wu, Y., Zhao, Z., & Wu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1061394 · Cited by 102
“However, this type of CRC could be conquered by the combination of antiTGF-b and anti-PD-1/PD-L1 (132).”
BackgroundResultInfluentialAKT-dependent NOTCH3 activation drives tumor progression in a model of mesenchymal colorectal cancer
Varga, J., Nicolas, A., Petrocelli, V., Pesic, M., Mahmoud, A., Michels, B. E., Etlioglu, E., Yepes, D., Häupl, B., Ziegler, P. K., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191515 · Cited by 93
Colton, M., Cheadle, E. J., Honeychurch, J., & Illidge, T. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01678-1 · Cited by 98
Chuntova, P., Chow, F. E., Watchmaker, P. B., Galvez, M., Heimberger, A. B., Newell, E. W., Diaz, A. A., DePinho, R. A., Li, M. O., Wherry, E. J., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa277 · Cited by 96
The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?
Gonzalez‐Sanchez, E., Vaquero, J., Fernández‐Barrena, M. G., Lasarte, J. J., Avila, M. A., Sarobe, P., Reig, M., Calvo, M., & Fabregat, I. (2021) · Cancers · doi:10.3390/cancers13133248 · Cited by 110
Zhao, L., Zheng, R., Kong, R., Huang, C., Rao, X., Ni, Y., Chen, A., Yu, X., Cheng, H. B., & Li, S. (2022) · ACS Nano · doi:10.1021/acsnano.1c08978 · Cited by 94
Promising approaches in cancer immunotherapy
Taefehshokr, N., Baradaran, B., Baghbanzadeh, A., & Taefehshokr, S. (2019) · Immunobiology · doi:10.1016/j.imbio.2019.11.010 · Cited by 105
Cho, B. C., Daste, A., Ravaud, A., Salas, S., Isambert, N., McClay, E., Awada, A., Borel, C., Ojalvo, L. S., Helwig, C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000664 · Cited by 90
“By investigator assessment, ORR and DCR were 16% and 34%, respectively (table 2).”
InfluentialExploring and modelling colon cancer inter-tumour heterogeneity: opportunities and challenges
Buikhuisen, J. Y., Torang, A., & Medema, J. P. (2020) · Oncogenesis · doi:10.1038/s41389-020-00250-6 · Cited by 107
The Role of TGF-β Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis
Saito, A., Horie, M., Micke, P., & Nagase, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113611 · Cited by 90
“Cancer progression is dependent on the evasion of immunosurveillance, and immune suppression by TGF-β is an emerging mechanism in tumorigenesis [91,92].”
BackgroundTGFβ-Directed Therapeutics: 2020
Teicher, B. A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107666 · Cited by 109
Varayathu, H., Sarathy, V., Thomas, B. E., Mufti, S. S., & Naik, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.559161 · Cited by 104
Peng, S., Li, Y., Huang, M., Tang, G., Xie, Y., Chen, D., Hu, Y., Yu, T., Cai, J. Q., Yuan, Z., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.68484 · Cited by 101
“We used the TGFBR1 specific inhibitor Galunisertib, which was investigated in a phase 2 trial to treat HCC, a small-molecule cancer drug that specifically inhibits TGF-beta signaling [31, 32].”
MethodHeinz, M. C., Peters, N. A., Oost, K. C., Lindeboom, R. G. H., van Voorthuijsen, L., Fumagalli, A., van der Net, M. C., de Medeiros, G., Hageman, J. H., Verlaan-Klink, I., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-0933 · Cited by 90
Tang, X., Tu, G., Yang, G., Wang, X., Kang, L., Yang, L., Zeng, H., Wan, X., Qiao, Y., Cui, X., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.044 · Cited by 76
“TGF-β1 is a master cytokine secreted by both tumor cells and stromal CAFs [21; 22; 23].”
BackgroundSubtil, B., Iyer, K. K., Poel, D., Bakkerus, L., Gorris, M. A. J., Cuenca‐Escalona, J., van den Dries, K., Cambi, A., Verheul, H. M. W., de Vries, I. J. M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1105244 · Cited by 98
Self-citationGolumba-Nagy, V., Kuehle, J., Hombach, A. A., & Abken, H. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.005 · Cited by 96
Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity
Terry, S., Zaarour, R. F., Venkatesh, G. H., Francis, A., El‐Sayed, W., Buart, S., Bravo, P. E., Thiery, J., & Chouaïb, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103044 · Cited by 99
Autocrine TGFβ Is a Survival Factor for Monocytes and Drives Immunosuppressive Lineage Commitment
Gonzalez-Junca, A., Driscoll, K. E., Pellicciotta, I., Du, S., Lo, C. H., Roy, R., Parry, R., Tenvooren, I., Marquez, D. M., Spitzer, M. H., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0310 · Cited by 89
Transforming growth factor β signaling pathway: A promising therapeutic target for cancer
Chen, Y., Di, C., Zhang, X., Wang, J., Wang, F., Yan, J., Xu, C., Zhang, J., Zhang, Q., Li, H., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29108 · Cited by 93
Chang, R. B., & Beatty, G. L. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mir0320-475r · Cited by 106
STAT3 Signaling in Breast Cancer: Multicellular Actions and Therapeutic Potential
To, S. Q., Dmello, R. S., Richards, A. K., Ernst, M., & Chand, A. L. (2022) · Cancers · doi:10.3390/cancers14020429 · Cited by 86
“A critical cytokine-dependent mechanism that promotes immune evasion during metastasis is transforming growth factor β (TGFβ)/IL-11 signaling axis [95,96].”
BackgroundDisulfiram loaded calcium phosphate nanoparticles for enhanced cancer immunotherapy
Li, Q., Chao, Y., Liu, B., Xiao, Z., Yang, Z., Wu, Y., & Liu, Z. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121880 · Cited by 92
Wang, Y., Gao, Z., Du, X., Chen, S., Zhang, W., Wang, J., Li, H., He, X., Cao, J., & Wang, J. (2020) · Biomaterials Science · doi:10.1039/d0bm00916d · Cited by 88
The Resistance Mechanisms of Lung Cancer Immunotherapy
Wang, F., Wang, S., & Zhou, Q. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568059 · Cited by 98
Trials and tribulations of pancreatic cancer immunotherapy
Principe, D. R., Korc, M., Kamath, S. D., Munshi, H. G., & Rana, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.01.031 · Cited by 100
Balta, E., Wabnitz, G. H., & Samstag, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115736 · Cited by 88
The Role of TGF-β in Bone Metastases
Trivedi, T., Pagnotti, G. M., Guise, T. A., & Mohammad, K. S. (2021) · Biomolecules · doi:10.3390/biom11111643 · Cited by 108
Targeting TGFβR2‐mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer
Huang, H., Zhang, Y., Gallegos, V., Sorrelle, N., Zaid, M. M., Toombs, J., Du, W., Wright, S., Hagopian, M., Wang, Z., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910515 · Cited by 87
“TGFb is a druggable target, inhibition of which has shown efficacy in multiple tumor types especially in combination with immune checkpoint blockade (Mariathasan et al, 2018; Tauriello et al, 2018).”
BackgroundAdvancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment
Titov, A., Valiullina, A., Zmievskaya, E., Zaikova, E. K., Petukhov, A., Рифкатовна, М. Р., Bulatov, E., & Rizvanov, A. A. (2020) · Cancers · doi:10.3390/cancers12010125 · Cited by 99
Deng, X., Liang, H., Yang, W., & Shao, Z. (2020) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2020.111913 · Cited by 91
Functional diversity of cancer‐associated fibroblasts in modulating drug resistance
Bu, L., Baba, H., Yasuda, T., Uchihara, T., & Ishimoto, T. (2020) · Cancer Science · doi:10.1111/cas.14578 · Cited by 86
Sorrentino, C., D’Antonio, L., Fieni, C., Ciummo, S. L., & Carlo, E. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.778329 · Cited by 99
“Notably, inhibition of TGFb1 can prevent CRC metastasis by unleashing a cytotoxic T cell response against cancer cells, implying that TGFb1 signaling suppresses cancer recognition by the immune system (75, 76).”
BackgroundIntestinal organ chips for disease modelling and personalized medicine
Özkan, A., LoGrande, N., Feitor, J. F., Goyal, G., & Ingber, D. E. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00968-3 · Cited by 110
“In particular, stromal cells can help to maintain homeostasis as well as contribute to disease phenotypes in the intestine 228–237 .”
Yasmin‐Karim, S., Bruck, P. T., Moreau, M., Kunjachan, S., Chen, G. Z., Kumar, R., Grabow, S., Dougan, S. K., & Ngwa, W. F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02030 · Cited by 90
Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy
Abou Khouzam, R., Goutham, H. V., Zaarour, R. F., Chamseddine, A. N., Francis, A., Buart, S., Terry, S., & Chouaib, S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.003 · Cited by 83
Lineage Reversion Drives WNT Independence in Intestinal Cancer
Han, T., Goswami, S., Hu, Y., Tang, F., Zafra, M. P., Murphy, C., Cao, Z., Poirier, J. T., Khurana, E., Elemento, O., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1536 · Cited by 85
Matrix-producing neutrophils populate and shield the skin
Vicanolo, T., Özcan, A., Li, J. L. Y., Huerta-López, C., Ballesteros, I., Rubio-Ponce, A., Dumitru, A. C., Nicolás-Ávila, J. Á., Molina-Moreno, M., Reyes‐Gutierrez, P., et al. (2025) · Nature · doi:10.1038/s41586-025-08741-5 · Cited by 104
“…in a previous study 12 , whereas mice with a neutrophil-specific deficiency in Tgfbr2 signalling ( Tgfbr ΔN ) were generated by crossing Mrp8 Cre mice with B6;129-Tgfbr2 tm1Karl/J ( Tgfbr2 fl/fl ) mice 40 , and the efficiency of gene deletion was assessed by qPCR in lung neutrophils (not shown).”
Regulators of CD8+ T cell exhaustion
Sun, Q., & Dong, C. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01221-x · Cited by 116
“Indeed, blockade of TGFβ signalling enhances CD8 + T cell accumulation and functionality and synergizes with PD1 or PDL1 blockade, which positions it as a promising target for cancer immunotherapy 101–105 .”
Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome
Fakih, M., Ouyang, C., Wang, C., Tu, T. Y., Gozo, M. C., Cho, M., Sy, M., Longmate, J. A., & Lee, P. P. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127046 · Cited by 84
Targeting regulation of tryptophan metabolism for colorectal cancer therapy: a systematic review
Zhang, H., Zhang, A., Miao, J.-H., Sun, H. J., Yan, G., Wu, F., & Wang, X. (2019) · RSC Advances · doi:10.1039/c8ra08520j · Cited by 98
Laminin γ2–mediating T cell exclusion attenuates response to anti–PD-1 therapy
Li, L., Wei, J.-R., Dong, J., Lin, Q., Tang, H., Jia, Y., Tan, W., Chen, Q., Zeng, T., Xing, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abc8346 · Cited by 103
“RESULTS Cancer patients with high Ln-2 display a poor response to anti–PD-1 therapy Increased TGF- signaling in the tumor microenvironment has been reported to attenuate the susceptibility of tumor cells to anti–PD-1/ PD-L1 therapies, but the mechanisms are unclear (13, 21, 22).”
BackgroundLou, W., Chen, J., Ding, B., Chen, D., Zheng, H., Jiang, D., Xu, L., Bao, C., Cao, G., & Fan, W. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1639-8 · Cited by 89
Chen, Y., Huang, Y., Gao, X., Li, Y., Lin, J., Chen, L., Chang, L., Chen, G., Guan, Y., Pan, L. K., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01620 · Cited by 101
“To our knowledge, our results are the first to reveal that a CCND1 amplification may significantly correlate with tumorigenesis and attenuation of various types of effector immune cells in the TME, including cytotoxic cells, T cells, CD8+ T cells, DC cells, and B cells, and upregulation of Treg cells and MDSCs. Oncoge…”
BackgroundInfluentialCellular and molecular waypoints along the path of T cell exhaustion
Lan, X., Zebley, C. C., & Youngblood, B. (2023) · Science Immunology · doi:10.1126/sciimmunol.adg3868 · Cited by 95
“Previously described as an immunosuppressive cytokine during chronic infection and tumor development (110, 111), it is now appreciated that the impact transforming growth factor–β (TGFβ) has on T cell differentiation is stage dependent.”
BackgroundLian, G., Wang, Q., Tang, P. M., Zhou, S. Y., Huang, X., & Lan, H.-Y. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.06.016 · Cited by 88
The Dual Roles of the Atypical Protein Kinase Cs in Cancer
Reina‐Campos, M., Díaz-Meco, M. T., & Moscat, J. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.07.010 · Cited by 92
“These findings are in keeping with a recent study showing the same effect of the combination therapy for the treatment of CRC metastasis (Tauriello et al., 2018).”
ResultCell-intrinsic and microenvironmental determinants of metastatic colonization
Lambert, A. W., Zhang, Y., & Weinberg, R. A. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01409-8 · Cited by 97
Metropulos, A. E., Munshi, H. G., & Principe, D. R. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104380 · Cited by 81
Soldevilla, B., Carretero-Puche, C., Goméz-López, G., Al‐Shahrour, F., Martínez, M. C. R., Gil-Calderón, B., Álvarez‐Vallina, L., Espinosa-Olarte, P., Gomez-Esteves, G., Rubio-Cuesta, B., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.09.008 · Cited by 97
Fluorine assembly nanocluster breaks the shackles of immunosuppression to turn the cold tumor hot
Li, Z., Zhu, L., Sun, H., Shen, Y., Hu, D., Wu, W., Wang, Y., Qian, C., & Sun, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2011297117 · Cited by 87
Evaluating the impact of age on immune checkpoint therapy biomarkers
Erbe, R., Wang, Z., Wu, S. K., Xiu, J., Zaidi, N., La, J., Tuck, D. P., Fillmore, N. R., Giraldo, N. A., Topper, M. J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109599 · Cited by 84
Hu, Y., Hudson, W. H., Kissick, H. T., Medina, C. B., Baptista, A. P., Ma, C., Liao, W., Germain, R. N., Turley, S. J., Zhang, N., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20211574 · Cited by 92
“Recent studies have shown that TGF-β blockade potentiates the effects of PD-1/PD-L1 immune checkpoint therapy by altering peritumoral stroma and increasing T cell infiltration into tumors (Mariathasan et al., 2018; Tauriello et al., 2018).”
BackgroundThe fibrotic and immune microenvironments as targetable drivers of metastasis
Boulter, L., Bullock, E., Mabruk, Z., & Brunton, V. G. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01172-1 · Cited by 82
“In a model of metastatic colorectal cancer, inhibition of TGF-β initiated a cytotoxic T cell response, and, importantly, in both these studies, inhibition of TGF-β signalling enhanced the activity of immune checkpoint inhibitors.(98) Although direct effects on metastatic outgrowth have not been reported, effective tar…”
BackgroundA 3D View of Colorectal Cancer Models in Predicting Therapeutic Responses and Resistance
Reidy, E., Leonard, N. A., Treacy, O., & Ryan, A. E. (2021) · Cancers · doi:10.3390/cancers13020227 · Cited by 93
“Furthermore, CAFs promote metastasis through secretion of transforming growth factor-beta (TGF-β), leading to an immunosuppressive environment [63] and have also been shown to contribute to resistance to conventional therapies such as chemotherapy [64].”
BackgroundRegulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer
Principe, D. R., Chiec, L. S., Mohindra, N. A., & Munshi, H. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684098 · Cited by 91
“TGFb has been shown to contribute to immune evasion in cancer (96) and attenuate therapeutic responses to PD-L1 inhibition by contributing to T-cell exclusion (97).”
BackgroundLi, X.-S., Wu, Y., & Tian, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214436 · Cited by 95
Digestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 100
Gu, S., & Feng, X. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmy092 · Cited by 84
“Increased TGF-β in the tumor microenvironment represents a primary mechanism of immune evasion in colon cancer [99].”
BackgroundEffects of Radiation on the Tumor Microenvironment
Monjazeb, A. M., Schalper, K. A., Villarroel‐Espíndola, F., Nguyen, A. T., Shiao, S. L., & Young, K. H. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2019.12.004 · Cited by 93
Long non-coding RNAs and cancer metastasis: Molecular basis and therapeutic implications
Ming, H., Li, B., Zhou, L., Goel, A., & Huang, C. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188519 · Cited by 90
Yap, T. A., Vieito, M., Baldini, C., Sepúlveda-Sánchez, J. M., Kondo, S., Simonelli, M., Cosman, R., van der Westhuizen, A., Atkinson, V. G., Carpentier, A. F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1504 · Cited by 86
“The CAFs are involved in the remodeling of the extracellular matrix during tumorigenesis and cause a stromal-rich immunosuppressive environment, a common feature of cold tumors such as pancreatic cancer and colorectal cancer (7, 8).”
BackgroundInfluentialCancer‐associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets
Menezes, S., Okail, M. H., Jalil, S. M. A., Kocher, H. M., & Cameron, A. J. M. (2022) · The Journal of Pathology · doi:10.1002/path.5926 · Cited by 91
“The immunosuppressive role of TGF-β has been examined in a variety of solid tumours, including PDAC [52,65,104,105].”
BackgroundCaldwell, A., Coleby, R., Tovar, C., Stammnitz, M. R., Kwon, Y. M., Owen, R. S., Tringides, M. L., Murchison, E. P., Skjødt, K., Thomas, G. J., et al. (2018) · eLife · doi:10.7554/elife.35314 · Cited by 77
Wang, X., Yang, C., Zhao, Y., Xu, Z., Yang, W. Z., Wang, P., Lin, D., Xiong, B., Fang, J., Dong, C., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0089-4 · Cited by 87
Ceci, C., Atzori, M. G., Lacal, P. M., & Graziani, G. (2020) · Cancers · doi:10.3390/cancers12113401 · Cited by 85
“In colorectal cancer, increased TGF-β levels in the TME not only promoted T-cell exclusion but also blocked the acquisition of the Th1 effector phenotype [42].”
BackgroundCombining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach
Kim, C.-G., Sang, Y. B., Lee, J. H., & Chon, H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158035 · Cited by 83
Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities
Caramelo, B., Zagorac, S., Corral, S., Marqués, M., & Real, F. X. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.02.011 · Cited by 87
Rational targeting of immunosuppressive neutrophils in cancer
Zhao, Y., Rahmy, S., Liu, Z., Zhang, C., & Lü, X. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107556 · Cited by 80
News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors
Melaiu, O., Lucarini, V., Giovannoni, R., Fruci, D., & Gemignani, F. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.001 · Cited by 79
Radiotherapy: An immune response modifier for immuno-oncology
Martino, M. D., Daviaud, C., & Vanpouille‐Box, C. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101474 · Cited by 88
Zhou, M., Wang, C., Lu, S., Xu, Y., Li, Z., Jiang, H., & Ma, Y. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103375 · Cited by 88
“TAMs-derived TGF-b contributed to exclusion of CD8 T-cells and blocked the acquisition of the Th1 effector phenotype [92].”
BackgroundZhao, Q., Wang, F., Chen, Y., Chen, S., Yao, Y.-C., Zeng, Z.-L., Jiang, T., Wang, Y., Wu, C., Jing, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30062-8 · Cited by 90
Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy
Gu, Y., Zhang, Z., & ten Dijke, P. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-00980-8 · Cited by 80
“Galunisertib (LY2157299), a TGF-β type I receptor (TβRI)-specific kinase inhibitor [229], was used to inhibit TGF-β receptor signaling in transplanted Lgr5 ::Apc-Kras-Tgfbr2-Trp53 mouse colorectal cancer organoids (LAKTP MTOs), in the cecum of syngeneic mice [230].”
BackgroundMethodQiang, L., Hoffman, M. T., Ali, L. R., Castillo, J. I., Kageler, L., Temesgen, A., Lenehan, P., Wang, S. J., Bello, E., Cardot-Ruffino, V., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.05.038 · Cited by 75
Metadata
- Authors
- Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., Byrom, D., Matarin, J. A., Calon, A., Rivas, E. I., Nebreda, A. R., Riera, A., Attolini, C. S.-O., & Batlle, E.
- Affiliations
- Institute for Research in Biomedicine (ES)
- Universitat Autònoma de Barcelona (ES)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Batlle, Eduard
- ORCID
- Venue
- Nature
- Published
- 2018-02
- Volume
- 554
- Issue
- 7693
- Pages
- 538-543
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2788975052
- Cited by
- 1,851
- References
- 43
- Citations by year
- 2026: 193 · 2025: 186 · 2024: 159 · 2023: 211 · 2022: 280 · 2021: 305 · 2020: 247 · 2019: 176 · 2018: 94
- FWCI
- 77.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- TGF-beta signaling, colorectal cancer metastasis, immune evasion, T-cell exclusion, tumor microenvironment, immune checkpoint inhibitors, TGF-beta inhibition, liver metastasis, microsatellite stable colorectal cancer, genetically engineered mouse models, organoid transplantation, combination immunotherapy
- MeSH terms
- Alleles, Animals, Cell Differentiation, Colonic Neoplasms, Disease Models, Animal, Drug Synergism, Female, Humans, Immunotherapy, Intestinal Mucosa, Intestines, Liver Neoplasms, Male, Mutation, Neoplasm Metastasis, Stem Cells, T-Lymphocytes, Cytotoxic, Transforming Growth Factor beta, Th1 Cells, Mice, Immune Evasion, Tumor Microenvironment, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.